Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: A randomized, controlled trial

Roberto Cosentini, Anna Maria Brambilla, Stefano Aliberti, Angelo Bignamini, Stefano Nava, Antonino Maffei, Renato Martinotti, Paolo Tarsia, Valter Monzani, Paolo Pelosi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Objective: Our objective was to evaluate the efficacy of noninvasive continuous positive airway pressure(CPAP) delivered by helmet in improving oxygenation in comparison with oxygen therapy in community-acquired pneumonia(CAP). Methods: This was a multicenter, randomized, controlled trial enrolling patients with CAP admitted to an ED with moderate hypoxemic acute respiratory failure(ARF)(PaO2/FIO2 ratio ≥ 210 and ≤285). Patients were randomized to helmet CPAP or standard oxygen therapy(control group). The primary end point was the time to reach a PaO 2 /FIO2 ratio >315. After reaching this value, patients randomized to CPAP were switched to oxygen, and the proportion of subjects who could maintain a PaO2/FIO2 ratio >315 at 1 h was recorded. Results: Forty-seven patients were recruited: 20 randomized to CPAP and 27 to controls. Patients randomized to CPAP reached the end point in a median of 1.5 h, whereas controls reached the end point in 48 h(P2 /FIO2 value >315. Conclusions: CPAP delivered by helmet rapidly improves oxygenation in patients with CAP suffering from a moderate hypoxemic ARF. This trial represents a proof-of-concept evaluation of the potential usefulness of CPAP in patients with CAP. Trial registration: clinicaltrials.gov; Identifier: NCT00603564.

Original languageEnglish
Pages (from-to)114-120
Number of pages7
JournalChest
Volume138
Issue number1
DOIs
Publication statusPublished - Jul 1 2010

Fingerprint

Head Protective Devices
Continuous Positive Airway Pressure
Pneumonia
Randomized Controlled Trials
Oxygen
Respiratory Insufficiency
Therapeutics
Control Groups

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia : A randomized, controlled trial. / Cosentini, Roberto; Brambilla, Anna Maria; Aliberti, Stefano; Bignamini, Angelo; Nava, Stefano; Maffei, Antonino; Martinotti, Renato; Tarsia, Paolo; Monzani, Valter; Pelosi, Paolo.

In: Chest, Vol. 138, No. 1, 01.07.2010, p. 114-120.

Research output: Contribution to journalArticle

Cosentini, Roberto ; Brambilla, Anna Maria ; Aliberti, Stefano ; Bignamini, Angelo ; Nava, Stefano ; Maffei, Antonino ; Martinotti, Renato ; Tarsia, Paolo ; Monzani, Valter ; Pelosi, Paolo. / Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia : A randomized, controlled trial. In: Chest. 2010 ; Vol. 138, No. 1. pp. 114-120.
@article{f2ec6110887e4d8887eca0d603bdfdfa,
title = "Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: A randomized, controlled trial",
abstract = "Objective: Our objective was to evaluate the efficacy of noninvasive continuous positive airway pressure(CPAP) delivered by helmet in improving oxygenation in comparison with oxygen therapy in community-acquired pneumonia(CAP). Methods: This was a multicenter, randomized, controlled trial enrolling patients with CAP admitted to an ED with moderate hypoxemic acute respiratory failure(ARF)(PaO2/FIO2 ratio ≥ 210 and ≤285). Patients were randomized to helmet CPAP or standard oxygen therapy(control group). The primary end point was the time to reach a PaO 2 /FIO2 ratio >315. After reaching this value, patients randomized to CPAP were switched to oxygen, and the proportion of subjects who could maintain a PaO2/FIO2 ratio >315 at 1 h was recorded. Results: Forty-seven patients were recruited: 20 randomized to CPAP and 27 to controls. Patients randomized to CPAP reached the end point in a median of 1.5 h, whereas controls reached the end point in 48 h(P2 /FIO2 value >315. Conclusions: CPAP delivered by helmet rapidly improves oxygenation in patients with CAP suffering from a moderate hypoxemic ARF. This trial represents a proof-of-concept evaluation of the potential usefulness of CPAP in patients with CAP. Trial registration: clinicaltrials.gov; Identifier: NCT00603564.",
author = "Roberto Cosentini and Brambilla, {Anna Maria} and Stefano Aliberti and Angelo Bignamini and Stefano Nava and Antonino Maffei and Renato Martinotti and Paolo Tarsia and Valter Monzani and Paolo Pelosi",
year = "2010",
month = "7",
day = "1",
doi = "10.1378/chest.09-2290",
language = "English",
volume = "138",
pages = "114--120",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia

T2 - A randomized, controlled trial

AU - Cosentini, Roberto

AU - Brambilla, Anna Maria

AU - Aliberti, Stefano

AU - Bignamini, Angelo

AU - Nava, Stefano

AU - Maffei, Antonino

AU - Martinotti, Renato

AU - Tarsia, Paolo

AU - Monzani, Valter

AU - Pelosi, Paolo

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objective: Our objective was to evaluate the efficacy of noninvasive continuous positive airway pressure(CPAP) delivered by helmet in improving oxygenation in comparison with oxygen therapy in community-acquired pneumonia(CAP). Methods: This was a multicenter, randomized, controlled trial enrolling patients with CAP admitted to an ED with moderate hypoxemic acute respiratory failure(ARF)(PaO2/FIO2 ratio ≥ 210 and ≤285). Patients were randomized to helmet CPAP or standard oxygen therapy(control group). The primary end point was the time to reach a PaO 2 /FIO2 ratio >315. After reaching this value, patients randomized to CPAP were switched to oxygen, and the proportion of subjects who could maintain a PaO2/FIO2 ratio >315 at 1 h was recorded. Results: Forty-seven patients were recruited: 20 randomized to CPAP and 27 to controls. Patients randomized to CPAP reached the end point in a median of 1.5 h, whereas controls reached the end point in 48 h(P2 /FIO2 value >315. Conclusions: CPAP delivered by helmet rapidly improves oxygenation in patients with CAP suffering from a moderate hypoxemic ARF. This trial represents a proof-of-concept evaluation of the potential usefulness of CPAP in patients with CAP. Trial registration: clinicaltrials.gov; Identifier: NCT00603564.

AB - Objective: Our objective was to evaluate the efficacy of noninvasive continuous positive airway pressure(CPAP) delivered by helmet in improving oxygenation in comparison with oxygen therapy in community-acquired pneumonia(CAP). Methods: This was a multicenter, randomized, controlled trial enrolling patients with CAP admitted to an ED with moderate hypoxemic acute respiratory failure(ARF)(PaO2/FIO2 ratio ≥ 210 and ≤285). Patients were randomized to helmet CPAP or standard oxygen therapy(control group). The primary end point was the time to reach a PaO 2 /FIO2 ratio >315. After reaching this value, patients randomized to CPAP were switched to oxygen, and the proportion of subjects who could maintain a PaO2/FIO2 ratio >315 at 1 h was recorded. Results: Forty-seven patients were recruited: 20 randomized to CPAP and 27 to controls. Patients randomized to CPAP reached the end point in a median of 1.5 h, whereas controls reached the end point in 48 h(P2 /FIO2 value >315. Conclusions: CPAP delivered by helmet rapidly improves oxygenation in patients with CAP suffering from a moderate hypoxemic ARF. This trial represents a proof-of-concept evaluation of the potential usefulness of CPAP in patients with CAP. Trial registration: clinicaltrials.gov; Identifier: NCT00603564.

UR - http://www.scopus.com/inward/record.url?scp=77954699136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954699136&partnerID=8YFLogxK

U2 - 10.1378/chest.09-2290

DO - 10.1378/chest.09-2290

M3 - Article

C2 - 20154071

AN - SCOPUS:77954699136

VL - 138

SP - 114

EP - 120

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1

ER -